|
Synonyms: 90Y-DOTA-hLL2 | 90Y-epratuzumab tetraxetan | 90Y-hLL2 | AMG-412 | IMMU-hLL2 | LymphoCide® (proposed proprietary name)
Compound class:
Antibody
Comment: Epratuzumab is a humanized monoclonal antibody. It is derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). Epratuzumab has antineoplastic and antiinflammatory actions [1].
The antibody can be conjugated with tetraxetan (DOTA) which allows chelation of radionucleotides such as yttrium-90 [5]. |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 7920 | epratuzumab |
| Synonyms |
| 90Y-DOTA-hLL2 | 90Y-epratuzumab tetraxetan | 90Y-hLL2 | AMG-412 | IMMU-hLL2 | LymphoCide® (proposed proprietary name) |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 40 |
| Other databases | |
| DrugBank Ligand | DB04958 |
| GtoPdb PubChem SID | 249565768 |
| Search PubMed clinical trials | epratuzumab |
| Search PubMed titles | epratuzumab |
| Search PubMed titles/abstracts | epratuzumab |
| Wikipedia | Epratuzumab |
